Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014) |
| |
| Institution: | 1. School of Pharmacy, Monash University Malaysia, Malaysia;2. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand;3. School of Pharmacy, University of Wisconsin, Madison, USA;4. School of Population Health, University of Queensland, Brisbane, Australia;5. Centre for Health Economics Research & Modelling Infectious Diseases, Vaccine & Infectious Disease Institute, WHO Collaborating Centre, Faculty of Medicine & Health Sciences, University of Antwerp, Belgium;6. School of Public Health and Community Medicine, The University of New South Wales, Sydney, Australia;1. Departments of Medicine and of Epidemiology and Community Medicine, University of Ottawa, Ottawa, ON, Canada;2. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada;3. Canadian Public Health Association, Ottawa, ON, Canada;1. Infectious Dis. Unit, Sheba Med Ctr, Ramat-Gan, Israel;2. Section of Infectious Dis. Epidemiology, Gertner Institute for Epidemiology Research, Ramat-Gan, Israel;3. Private Clinic, Nabulus, Palestine;4. Maccabi Healthcare Services, Jerusalem-Hashfela District, Israel;5. Hadassah University Medical Ctr, Jerusaelm, Israel;6. Private Clinic, Ramallah, Palestine;7. The Biostatistics Unit, Gertner Institute for Epidemiology Research, Ramat-Gan, Israel;8. Private Clinic, Bethlehem, Palestine;9. Al-Quds Nutrition and Health Research Institute, Al-Quds University, Abu-Dis, Palestine;1. Croatian Institute of Public Health (CIPH), Department of Epidemiology, Croatia;2. Croatian Institute for Health Insurance (CIHI), Croatia;3. Ministry of Health of Republic of Croatia (MH), Croatia;4. London School of Hygiene and Tropical Medicine (LSHTM), UK;5. Agence de Médecine Préventive (AMP), France;1. National Consultant on Health Economics, Pan American Health Organization/World Health Organization (PAHO/WHO), Asunción, Paraguay;2. Ministry of Health, Asunción, Paraguay;3. Immunization Advisory Committee on Immunization, Asunción, Paraguay;4. Comprehensive Family Immunization, PAHO/WHO, Washington, DC, United States;5. London School of Hygiene and Tropical Medicine, London, United Kingdom;6. Comprehensive Family Immunization, PAHO/WHO, Asunción, Paraguay;1. Georgia National Centre for Disease Control and Public Health (NCDC), Tbilisi, Georgia;2. Agence de Médecine Préventive (AMP), Paris, France;3. National Statistics Office of Georgia (Geostat), Tbilisi, Georgia;4. Georgia Ministry of Labor, Health and Social Affairs (MoH), Tbilisi, Georgia;5. London School of Hygene and Tropical Medicine (LSHTM), London, United Kingdom;1. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA;2. China National Health Development Research Centre, Ministry of Health, Beijing, PR China;3. Peking University Health Science Center, No. 38 Xueyuan Rd., P.O. Box 218, Haidian District, Beijing 100191, PR China |
| |
| Abstract: | BackgroundSeven-valent pneumococcal conjugate vaccines (PCV7) have been used in children for more than a decade. Given the observed increase in disease caused by pneumococcal serotypes not covered by PCV7, an increasing number of countries are switching from 7-valent to 10- and 13-valent PCVs (“PCV10” and “PCV13”). Economic evaluations are important tools to inform decisions and price negotiations to make such a switch.ObjectiveThis review aims to provide a critical assessment of economic evaluations involving PCV10 or PCV13, published since 2006.MethodsWe searched Scopus, ISI Web of Science (SCI and SSCI) and Pubmed to retrieve, select and review relevant studies, which were archived between 1st January 2006 and 31st January 2014. The review protocol involved standard extraction of assumptions, methods, results and sponsorships from the original studies.ResultsSixty-three economic evaluations on PCVs published since January 2006 were identified. About half of these evaluated PCV10 and/or PCV13, the subject of this review. At current prices, both PCV13 and PCV10 were likely judged preferable to PCV7. However, the combined uncertainty related to price differences, burden of disease, vaccine effectiveness, herd and serotype replacement effects determine the preference base for either PCV10 or PCV13. The pivotal assumptions and results of these analyses also depended on which manufacturer sponsored the study.ConclusionA more thorough exploration of uncertainty should be made in future analyses on this subject, as we lack understanding to adequately model herd and serotype replacement effects to reliably predict the population impact of PCVs. The introduction of further improved PCVs in an environment of evolving antibiotic resistance and under the continuing influence of previous PCVs implies that the complexity and data requirements for relevant analyses will further increase. Decision makers using these analyses should not just rely on an analysis from a single manufacturer. |
| |
| Keywords: | Pneumococcal conjugate vaccine Cost-effectiveness Cost–benefit |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
